

1 **TITLE**

2 **Gut microbiota features on nursing home admission are associated with**
3 **subsequent acquisition of antibiotic resistant organism colonization**

4

5 **AUTHORS**

6 Joyce Wang¹, Marco Cassone², Kristen Gibson², Bonnie Lansing², Lona Mody^{2,3}, Evan
7 Snitkin^{1,4,5*}, Krishna Rao^{5*}

8

9 ¹Department of Microbiology and Immunology, University of Michigan Medical School,
10 Ann Arbor, Michigan, USA

11 ²Division of Geriatrics and Palliative Care Medicine, University of Michigan Medical
12 School, Ann Arbor, Michigan, USA

13 ³Geriatric Research Education and Clinical Center, VA Ann Arbor Healthcare System,
14 Ann Arbor, Michigan, USA

15 ⁴Department of Computational Medicine and Bioinformatics, University of Michigan
16 Medical School, Ann Arbor, Michigan, USA

17 ⁵Division of Infectious Diseases, Department of Medicine, University of Michigan
18 Medical School, Ann Arbor, Michigan, USA

19 *These authors contributed equally.

20

21 **Keywords:** Intestinal Microbiota, Genomic Epidemiology, Antibiotic-resistant organisms,
22 Skilled Nursing Facilities, Antibiotic Exposure

23

24 **Running title:** Gut microbiota and resistant organisms

25 **Contact information:**

26 **Corresponding author:**

27 A. Krishna Rao, MD, MS

28 Assistant Professor

29 Division of Infectious Diseases

30 Department of Internal Medicine

31 University of Michigan Medical School

32

33 1510B, MSRB I

34 1150 W. Medical Center Dr.

35 Ann Arbor, MI 48109

36 Phone: (734) 615-9730

37 E-mail: krirao@med.umich.edu

38

39 **Alternate corresponding author:**

40 Evan Snitkin, PhD

41 Assistant Professor

42 Department of Microbiology and Immunology

43 Department of Medicine, Division of Infectious Diseases

44 University of Michigan Medical School

45

46 1520D MSRB I

47 1150 W. Medical Center Dr.

48 Ann Arbor, MI, 48109-5680

49 Phone: (734) 647-6472

50 E-mail: esnitkin@med.umich.edu

51

52

53

54

55

56

57

58 **ABSTRACT** (50 words max; unstructured format)

59 Nursing home (NH) patients often acquire colonization with antibiotic-resistant
60 organisms (AROs). We show that patients exposed to broad-spectrum antibiotics during
61 previous hospitalizations have elevated enterococcal relative abundances on NH
62 admission and higher risk of subsequent ARO acquisition. Our findings suggest that
63 interventions preventing ARO spread should extend beyond NH doors.

64 **Introduction**

65 Antibiotic resistance is a major public health threat, particularly among vulnerable
66 populations in healthcare settings [1]. Within the healthcare system, post-acute care
67 settings such as nursing homes (NHs) have been recognized as an important reservoir
68 for antibiotic resistant organisms (AROs) [2]. NH patients are often older adults with
69 complicated medical conditions, and ARO acquisition is common in this patient
70 population. In a recent study, one-third of patients uncolonized at the time of NH
71 admission acquire an enteric ARO such as vancomycin-resistant *Enterococcus* (VRE)
72 or resistant gram-negative bacteria (R-GNB) during their stay [3].

73 The role of intestinal microbiota in mediating the risk of ARO colonization has
74 become increasingly appreciated in clinical settings where microbiota disruptions often
75 precede ARO colonization [4]. While most research and intervention efforts have
76 focused on improving appropriate antibiotic use in the NH setting, the impact of frequent
77 antibiotic exposure during previous acute care hospitalization on ARO acquisition during
78 NH stay has been mostly overlooked [3,5]. We hypothesized that due to the lasting
79 effects of antibiotic exposure, antibiotic use at connected healthcare facilities could
80 impact risk of ARO acquisition once in NHs. To test this hypothesis, we conducted a
81 prospective, longitudinal cohort study to examine patient clinical factors and gut
82 microbiota features at the time of NH admission and their associations with the risk of
83 acquisition of VRE and/or R-GNB within 14 days of study enrollment.

84

85 **METHODS**

86

87 **Study Population**

88 From September 2016–August 2018, we enrolled patients from six NHs in
89 southeast Michigan within 14 days of admission as part of a larger NIH-funded trial.
90 Colonization status was determined by culture swabs collected from multiple body sites
91 at enrollment, day 7, and day 14 using microbiological procedures described previously
92 [3]. Our analysis focused on patients: 1) colonized with neither VRE nor R-GNB at the
93 time of study enrollment, 2) had a perirectal swab (Copan ESwab™) collected at
94 enrollment, and 3) had at least one follow-up visit with culture samples. Patient clinical
95 data were collected at enrollment by trained research personnel for each patient using
96 hospital transfer records and/or NH medical data. All subjects or their proxy provided a
97 written informed consent. This study was approved by the University of Michigan
98 Institutional Review Board.

99

100 **16S rRNA Gene Sequencing and Analysis**

101 Perirectal specimens underwent DNA extraction, 16S rRNA PCR-amplification,
102 and MiSeq sequencing as previously described [6]. The resulting sequences were
103 clustered into operational taxonomic units (OTUs) using *mothur* (see Supplementary
104 Materials for detailed methods) [7]. OTUs typically associated with the skin microbiota at
105 the genus level, including *Staphylococcus*, *Corynebacterium* and *Propionibacterium*
106 were removed from downstream analyses.

107

108 **Statistical Analysis**

109 All data analyses were performed in R (version 3.6.1). The primary outcome was
110 the acquisition of VRE or R-GNB within 14 days of study enrollment. Exposures of
111 interest included patient clinical factors and microbiota features at enrollment. Patient
112 characteristics associated with outcome were determined by linear or logistic regression
113 analyses. For microbiota features, we calculated the relative abundance of each OTU in
114 each patient. As perirectal samples are low in biomass and rare OTUs may not be well-
115 represented across samples, we conservatively restricted our analyses to only the 50
116 most abundant OTUs in this cohort. Linear regression analyses were used to examine
117 associations between the relative abundance of each OTU and antibiotic exposure.
118 Logistic regression analyses were used to identify associations between outcome and
119 individual OTU, the fraction of anaerobes and butyrate-producers (see Supplementary
120 Materials for details). Skewed data were log-transformed to achieve normal distribution.
121 For each OTU associated with ARO acquisition with an unadjusted *P*-value of <.05,
122 multivariable logistic regression analyses were used to identify patient factors that
123 modified the effect of the OTU by >10%. To assess variables representing more global
124 measures of microbiota state, we adapted a recently developed Microbiome Health
125 Index (MHI) [8]. An MHI of 0 after log transformation indicates a balanced abundance
126 between taxa associated with protection (*Bacteroidia* and *Clostridia*) and dysbiosis
127 (*Gammaproteobacteria* and *Bacilli*). An MHI above 0 suggests higher abundances of
128 protective taxa, and vice versa.

129

130 RESULTS

131

132 **Exposure to antibiotics disruptive to the gut microbiota prior to NH admission is**
133 **associated with ARO acquisition during NH stay**

134 Of 243 patients enrolled in the study, 61 patients met our inclusion criteria: no
135 VRE or R-GNB colonization on enrollment, a perirectal swab collected at enrollment and
136 at least one follow-up within 14 days (Supplementary **Figure S1**). Most patients (73%)
137 were enrolled within 7 days of NH admission (median, 6.0 days; range, 1 - 13 days).
138 Within 14 days of enrollment, 18 (29.5%) acquired AROs (3 VRE, 13 R-GNB, 2 both). In
139 bivariable analyses, exposure to high-risk antibiotic classes with previously-
140 demonstrated associations with gut microbiota disruption [9], including 3rd/4th-generation
141 cephalosporins, quinolones, lincosamides, penicillin combinations, carbapenems and
142 oral vancomycin prior to enrollment, was a significant risk factor associated with ARO
143 acquisition (OR, 4.20; 95%CI, 1.08 -17.63). Notably, the majority of these high-risk
144 antibiotics were initiated during hospitalization prior to admission to NH (N = 11/12),
145 many for infection-related reasons including urinary tract infection, pneumonia and
146 *Clostridium difficile* infection (Supplementary **Figure S2**).

147

148 **Microbiota features at enrollment differed between patients with and without ARO**
149 **acquisition during NH stay**

150 Following the observation that the receipt of high-risk antibiotics prior to NH
151 admission was associated with risk for ARO acquisition; we next asked if this exposure
152 had resulted in detectable disruption to the gut microbiota on admission to NHs. To
153 assess this, we performed 16S sequencing on perirectal swabs taken from the 61
154 patients on enrollment. After removing skin-associated taxa that were not deemed as

155 representative of the gut microbiota, 2326 OTUs were retained for final analysis.
156 Considering only the 50 most abundant OTUs, we found that exposure to high-risk
157 antibiotics prior to enrollment was associated with decreased relative abundance of
158 several OTUs associated with the *Clostridia*, *Bacteroidia*, and *Actinobacteria* classes,
159 and increased relative abundance of *Enterococcus* (**Figure 1A**).

160 Next we looked directly at whether there were OTUs associated with risk for ARO
161 acquisition, and found that patients who acquired an ARO during NH stay had
162 significantly increased relative abundance of *Enterococcus* at the time of enrollment
163 compared to those who did not acquire an ARO (log-transformed mean \pm standard
164 deviation [sd]: -2.31 ± 1.46 vs -3.41 ± 1.44 , $P = .012$; **Figure 1B**). Incorporating clinical
165 variables, including age, sex, race, body mass index, functional status, comorbidity
166 scores, length of previous hospital stay, or urinary catheter use within the past 30 days
167 in multivariable models did not significantly improve model fit, and the statistical
168 significance of *Enterococcus* was retained, suggesting that altered *Enterococcus*
169 abundance was an independent risk factor for ARO acquisition. Patients who acquired
170 an ARO had lower relative abundances of anaerobes and butyrate producers at
171 enrollment than those who did not, but the difference was not statistically significant.
172 Lastly, examination of the microbiome health index (MHI) revealed that 6 out of 18
173 (33.33%) of the patients who acquired an ARO had an MHI of < 0 , which was
174 significantly higher than the 5 out of 43 (11.63%) patients with no acquisition (chi-
175 squared test $P = .04$) (**Figure 1C**). The association between an MHI of less than 0 and
176 risk of acquisition remained significant after adjusting for hospital length of stay and

177 exposure to urinary catheter within the past 30 days, both potential confounders that
178 modified the effect of MHI by more than 10% (adjusted OR, 6.85; 95% CI, 1.46- 39.24).

179

180 **DISCUSSION**

181 With an aging population in the U.S., patients are more medically complex and
182 likely to require post-acute care after hospitalization. ARO acquisition during NH stay
183 not only negatively impacts patient outcome by increasing the risk of infection, but also
184 contributes to the spread of resistance within NHs, between healthcare facilities, and
185 the community [3]. By reviewing patient medical records, we found that recent exposure
186 to high-risk antibiotics, mostly initiated during prior hospitalization, was associated with
187 the risk of ARO acquisition. We further found that this association was mediated by
188 microbiota disruption, as patients who subsequently acquired an ARO had detectable
189 differences in their microbiota features at the time of NH admission.

190

191 Our finding that patients with elevated *Enterococcus* abundances were at a
192 higher risk of enteric ARO acquisition was consistent with previous studies
193 demonstrating that antibiotic therapy can promote high colonization density of VRE and
194 R-GNB [4,10]. Of note, while *Enterococcus* was detected in all 18 patients who acquired
195 an enteric ARO, only 3 acquired VRE, and the rest acquired either R-GNB (N = 13)
196 alone or R-GNB with VRE (N = 2), suggesting that enterococcal expansion is a
197 biomarker for susceptibility to enteric ARO colonization, instead of proliferation of pre-
198 existing VRE colonization. Several patients with elevated *Enterococcus* abundances did
199 not acquire ARO with 14 days, with these patients potentially representing an at-risk

200 population that had a lower intensity of ARO exposure from other patients, healthcare
201 workers, or the environment.

202

203 Our characterization of the gut microbiota of patients traversing the healthcare
204 network demonstrates that exposure to high-risk antibiotics on NH admission influenced
205 patient gut microbiota features and the risk of ARO acquisition during NH stay. Our
206 study highlights the connectedness of the healthcare network and suggests the future
207 study of coordinated infection prevention approaches between healthcare partners
208 would be a fruitful endeavor [11].

209

210 **ACKNOWLEDGMENTS**

211 We thank the patients and their families, and nursing homes who participated in
212 this study; we thank members of the Mody laboratory for data collection and analysis,
213 Drs. Christine Bassis and Jonathan Golob for technical and scientific discussions, and
214 the Microbial Systems Molecular Biology Laboratory at the University of Michigan for
215 performing 16S rRNA sequencing.

216

217 **FUNDING**

218 This work was supported by the Centers for Disease Control and Prevention
219 [Contract BAA 2016-N-17812 to E.S.S.], National Institutes of Health [grant number
220 R01AG041780, K24AG050685 to LM] , University of Michigan Host Microbiome
221 Initiative Microbiome Explorers Program to E.S.S. the Canadian Institutes of Health
222 Research fellowship [grant number 201711MFE-396343-165736 to JW] and the

Gut microbiota and resistant organisms

Wang *et al.*

- 223 Michigan Institute for Clinical and Health Research (MICHHR) Postdoctoral Translational
224 Scholars Program (PTSP) to JW.

REFERENCES

1. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. 2019: 148.
2. McKinnell JA, Singh RD, Miller LG, et al. The SHIELD Orange County Project: Multidrug-resistant Organism Prevalence in 21 Nursing Homes and Long-term Acute Care Facilities in Southern California. *Clin Infect Dis* Available at: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz119/5315468>. Accessed 28 April 2019.
3. Mody L, Foxman B, Bradley S, et al. Longitudinal Assessment of Multidrug-Resistant Organisms in Newly Admitted Nursing Facility Patients: Implications for an Evolving Population. *Clin Infect Dis* Available at: <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciy194/4965240>. Accessed 17 June 2018.
4. Annavajhala MK, Gomez-Simmonds A, Macesic N, et al. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. *Nat Commun* **2019**; 10:1–12. Available at: <https://www.nature.com/articles/s41467-019-12633-4>. Accessed 31 December 2019.
5. Pulia M, Kern M, Schwei RJ, Shah MN, Sampene E, Crnich CJ. Comparing appropriateness of antibiotics for nursing home residents by setting of prescription initiation: a cross-sectional analysis. *Antimicrob Resist Infect Control* **2018**; 7. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000953/>. Accessed 28 April 2019.
6. Seekatz AM, Bassis CM, Fogg L, et al. Gut Microbiota and Clinical Features Distinguish Colonization With *Klebsiella pneumoniae* Carbapenemase-Producing *Klebsiella pneumoniae* at the Time of Admission to a Long-term Acute Care Hospital. *Open Forum Infect Dis* **2018**; 5. Available at: <https://academic.oup.com/ofid/article/5/8/ofy190/5062196>. Accessed 26 August 2018.
7. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities. *Appl Environ Microbiol* **2009**; 75:7537–7541. Available at: <http://aem.asm.org/content/75/23/7537>. Accessed 20 June 2018.
8. Blount K, Jones C, Deych E, Shannon B. 1966. Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived From a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent *Clostridium difficile* Infections (rCDI). *Open Forum Infect Dis* **2018**; 5:S570. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253964/>. Accessed 16 May 2019.

9. Baggs J, Jernigan JA, Halpin AL, Epstein L, Hatfield KM, McDonald LC. Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure. *Clin Infect Dis* **2018**; 66:1004–1012. Available at: <https://academic.oup.com/cid/article/66/7/1004/4607897>. Accessed 5 May 2019.
10. Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of Antibiotic Therapy on the Density of Vancomycin-Resistant Enterococci in the Stool of Colonized Patients. *New England Journal of Medicine* **2000**; 343:1925–1932. Available at: <https://doi.org/10.1056/NEJM200012283432604>. Accessed 22 June 2018.
11. Mody L, Washer L, Flanders S. Can Infection Prevention Programs in Hospitals and Nursing Facilities Be Integrated?: From Silos to Partners. *JAMA* **2018**; 319:1089–1090. Available at: <http://jamanetwork.com/journals/jama/fullarticle/2674119>. Accessed 3 August 2018.




Figure 1. Microbiota features are associated with exposure to antibiotics during prior hospitalization and the risk of acquiring an enteric antibiotic-resistant organism (ARO) within 14 days. **A.** Relative abundances of operational taxonomic units (OTUs) significantly affected by prior exposure to high-risk antibiotics ($P < .05$). Without exposure: grey; with exposure: red. *Anaerococcus* and *Peptoniphilus* belong to class *Clostridia*, *Prevotella* belongs to class *Bacteroidia*, *Varibaculum* and *Bifidobacterium* belong to class *Actinobacteria*, and *Enterococcus* belongs to class *Bacilli*. **B.** Relative abundances of *Enterococcus* in patients who did not acquire an ARO in 14 days (white) and those who did (yellow). **C.** Microbiome health index (MHI) in patients who did not acquire an ARO in 14 days (white) and those who did (pink). Red line indicates an MHI of 0. Median and interquartile range are shown in boxplots. The y-axes are presented on a base 10 logarithmic scale.